Kornimate/medical-research-clean huggingface dataset:
methylphenidate in adults with attention deficit/hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: methylphenidate (mph) is the first-line pharmacological treatment for adults with attention-deficit/hyperactivity disorder (adhd). nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to mph. the aim of this study is to address the clinical and genetic predictors of mph treatment outcomes in adhd.

methylphenidate (mph) is the most prescribed psychostimulant for children and adults with attention-deficit/hyperactivity disorder (adhd). meta-analyses and systematic reviews have shown that mph is safe and efficacious in attenuating the core symptoms of adhd, promoting overall clinical improvement. however, many patients still do not show an appropriate clinical response to the mph treatment and there is considerable interindividual variability regarding the dose required, tolerability and response rates to mph. therefore, it is essential to address the clinical and genetic predictors of mph treatment outcomes in adhd.

Eligibility criteria:
inclusion criteria: * white brazilian of european descent * fulfillment of the diagnostic and statistical manual of mental disorders, fourth edition, (dsm-iv) diagnostic criteria for adhd * eligibility to immediate-release mph (ir-mph) treatment exclusion criteria: * contraindication for ir-mph use * current stimulant treatment * evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis) * current or past history of psychosis * estimated intelligence quotient score lower than 70

Keywords: adhd adults treatment methylphenidate
50% body weight reverses stature, lumbar disc expansion and vertebral compliance by hyper-buoyancy floatation.

Conditions: Intervertebral Disc Compression; Muscle Atrophy; Spine Injury

Summary: study with the aim to see the effect on a space ground analogue , hyper-buoyancy floatation (hbf) on lumbar column and the effect of a supplementary 50% of an axial load.

the aim of this study was to determine the effect of 15min of 1g reloading following 4h hbf unloading with, and without 30s of seated static 50% bw axial loading upon stature, lumbar intervertebral disc height (via ultrasound), vertebral compliance changes, and back pain.

Eligibility criteria:
inclusion criteria: * physical requirements (1.57-1.90m, 50-95kg) exclusion criteria: * current back/neck pain, musculoskeletal disorder, cardiovascular disease, spine surgery and being, or suspected to be pregnant
extending the hcg opu interval

Conditions: Infertility

Summary: our and others experience suggest that in some cases delaying oocyte pick up (opu) for more than 39 hours after hcg injection may be of benefit. we plan to apply this to 20 women in whom less than 20% of oocytes were found suitable for intracytoplasmic sperm injection. the delay will be for up to an interval of 47 hours from hcg to opu.

in ivf one encounters some women in whom a low percentage of oocytes are found in the metaphase ii stage upon their retrieval. following some incidents, in our experience as well as others', where women injected hcg too early but oocytes were still retrieved with high proportion of maturity, we decided to delay opu intentionally in women who had low percentage oocyte maturity in previous cycles.

Eligibility criteria:
inclusion criteria: previous 2 oocyte pick up cycles with 20% metaphase ii oocytes in the cohort - exclusion criteria: no previous ivf history -
persistence of antibody response to n. meningitidis group c in children

Conditions: Prevention of Meningococcal Infection

Summary: persistence of antibody response to n. meningitidis group c in children


Eligibility criteria:
inclusion criteria: * healthy children exclusion criteria: * previous ascertained or suspected disease caused by n. meningitidis * previous significant acute or chronic infections * any other serious disease

Keywords: prevention of meningococcal meningitis vaccines, conjugate immunology child antibody persistence
sutent rechallenge in mrcc patients

Conditions: Metastatic Renal Cell Carcinoma

Summary: retrospective and prospective study in mrcc patients treated with sutent in first line and rechallenged by sutent in 3rd and 4th line.

a sample size of n = 40 patients will allow to estimate of the median pfs with a precision around 1.8 months (based on data from rini et al.) this retrospective and prospective study is designed to estimate the effect of sutent rechallenge. the pfs (estimated from kaplan-meier estimate) will be the primary endpoints. in addition, the effects of sunitinib at the 2 periods of treatment (i.e. first line sunitinib vs. rechallenge) will be compared by wilcoxon signed-rank test for pfs values and by mcnemar test for overall response rate (orr).

Eligibility criteria:
inclusion criteria: * histologically documented metastatic rcc containing predominantly clear cell component. * previously received sunitinib in first line, 2 or more antitumor therapies subsequently and then received sunitinib for a second time. * at least 1 cycle of sunitinib rechallenge (1 cycle= 4 weeks on/2 weeks off). * at least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter (ld) ³ 10 mm when measured by spiral computerized tomography (ct) (5-mm slice thickness contiguous) or ³ 20 mm when measured by conventional ct (10-mm slice thickness contiguous). the lesion must be ³ 2 times the size of the slice thickness per recist criteria. * life expectancy of at least 3 months. exclusion criteria: * patient who didn't receive sunitinib in first line. * patient who received less than one line of treatment .

Keywords: sutent rechallenge
metoprolol in acute myocardial infarction. a pk/pd study

Conditions: Acute Myocardial Infarction

Summary: the objective of the study was to compare treatment with two different oral formulations of metoprolol, metoprolol immediate release (ir) and metoprolol extended release (cr/xl) in patients with acute myocardial infarction regarding the following: pharmacokinetics, peak and trough plasma concentrations and area under the plasma concentration curve. pharmacodynamics, hourly means of holter recorded heart rate. tolerability. an open, randomised design with two parallel groups was employed.

a pharmacokinetic and pharmacodynamic study comparing metoprolol ir and metoprolol cr/xl subsequent to initial treatment with intravenous and/or oral metoprolol in patients with suspected acut myocardial infarction

Eligibility criteria:
inclusion criteria: * male and female patients admitted to the ccu with suspected acute myocardial infarction * age 18 years or older * treated with and tolerated the full dose of metoprolol ir 50 mr four times daily or metoprolol cr/xl 200 mg once daily on study day 1 * expected to stay in the ccu until the morning of study day 4 * sinus rhythm on the day of admission and at randomisation exclusion criteria: * pregnancy or childbearing potential without adequate contraception * participation in a clinical study during the last 30 days or previous randomisation in the present study

Keywords: metoprolol, acute myocardial infarction, pharmacokinetics, pharmacodynamics
parp inhibitor with 177lu-dota-octreotate prrt in patients with neuroendocrine tumours

Conditions: Neuroendocrine Tumors

Summary: this phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177lu-dota-octreotate peptide receptor radionuclide therapy (prrt) in patients with metastatic pancreatic or midgut neuroendocrine tumour (net).

this phase 1, single arm, single centre study is designed to evaluate the safety and tolerability of talazoparib in combination with 177lu-dota-octreotate in patients with metastatic net. patients will receive 1 cycle of 177lu-dota-octreotate alone followed by 3 cycles of 177lu-dota-octreotate combined with 5 days of talazoparib.

Eligibility criteria:
inclusion criteria: 1. patient must be \> or equal to18 years of age and must have provided written informed consent. 2. eastern cooperative oncology group (ecog) performance status of ≤ 2 3. histologically confirmed grade 2 net, ki-67 of 3-20%, from pancreatic or intestinal origin. 4. patient clinically suitable for prrt 5. tumor ssr uptake on gatate pet/ct higher than liver activity, ≥ modified krenning 3 score 6. no discordant fdg-avid disease on fdg pet/ct 7. no evidence of significant uncorrected carcinoid heart disease 8. patients must be willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled assessments 9. patients must have adequate bone marrow, hepatic and renal function defined as: * haemoglobin ≥100 g/l * absolute neutrophil count ≥1.5x109/l * platelets ≥150 x109/l * total bilirubin ≤1.5 x upper limit of normal (uln) * aspartate transaminase (ast) (sgot) and alanine transaminase (alt) (sgpt) ≤2.5 x uln if there is no evidence of liver metastasis or ≤5 x uln in the presence of liver metastases. * albumin ≥ 30 g/l * adequate renal function: egfr ≥ 50 ml/min exclusion criteria: 1. surgery or radiotherapy within \<3 weeks of registration. patients must have recovered from any effects of any major surgery. 2. any prior exposure to peptide receptor radionuclide therapy (177lu, 111in or 90y labelled), parpi, immunotherapy 3. uncontrolled intercurrent illness that is likely to impede participation and /or compliance 4. other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ. 5. previous or current history of myelodysplastic syndrome/acute myeloid leukemia 6. patients unable to swallow orally administered medications or with gastrointestinal disorders likely to interfere with the absorption of the study medication. 7. use of strong p-gp inhibitors (eg, dronedarone, quinidine, ranolazine, verapamil, ketoconazole, itraconazole), p-gp inducers (eg, rifampin, tipranavir/ritonavir), or bcrp inhibitors (eg, elacridar \[gf120918\]) should be avoided. 8. participation in another clinical study with an investigational product or another systemic therapy administered in the last 3 weeks (except short acting ssa).

Keywords: net
vinflunine in the treatment of patients with relapsed extensive small cell lung cancer

Conditions: Carcinoma, Small Cell; Lung Cancer

Summary: this clinical trial involves the administration of the chemotherapeutic medication vinflunine. vinflunine is not approved by the fda and is experimental in the treatment of extensive small cell lung cancer. the purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer, evaluate the toxicity, and evaluate how long the response to this drug lasts.

eligible patients will receive vinflunine as a 15-20 minute intravenous (iv)infusion once every three weeks (21 days). this three week treatment period is called a cycle. patients whose cancer has not grown or if it has decreased in size may receive up to 6 cycles of vinflunine. evaluation will be conducted every other cycle.

Eligibility criteria:
inclusion criteria: * small cell lung cancer with progression after one previous chemotherapy or chemotherapy/radiation therapy regimen * measurable or evaluable disease * able to perform activities of daily living with minimal assistance * adequate hematological, liver, and kidney function * must give written informed consent prior to entry exclusion criteria: * cns involvement * serious active infection or underlying medical condition * significant history of uncontrolled cardiac disease

Keywords: extensive stage relapsed
vitamin a and zinc: prevention of pneumonia (vazpop) study

Conditions: Pneumonia; Diarrhea; Acute Upper Respiratory Tract Infections

Summary: children with malnutrition are often low in some nutrients, like zinc or vitamin a, that could help them fight off infections like pneumonia. our study was designed to see if children who got supplements of zinc or vitamin a had fewer infections.

the vitamin a and zinc: prevention of pneumonia (vazpop) study was a multi-year nutritionally-stratified, placebo-controlled, double-blind study of low-dose vitamin a and/or zinc in 2,582 normal and malnourished urban children aged 6 to 36 months in quito, ecuador. four group of \~ 645 children were enrolled in 2000, 2001, 2002, and 2003 with each child participating for up to 50 weeks. children were visited 4 days each week. outcome measures were pneumonia, other respiratory tract infections, diarrheal disease, and growth.

Eligibility criteria:
inclusion criteria: age 6 to 36 months at the time of enrollment no recent vitamin or micronutrient use residence of 1 year or longer in the neighborhood full and free written consent no clinical evidence of zinc or vitamin a deficiency absence of severe malnutrition such as weight \< or = to 60% of expected weight - exclusion criteria: age less than 6 months or greater than 36 months at enrollment recent vitamin or micronutrient use residence for less than 1 year in neighborhood lack of full and free consent any evidence of zinc or vitamin a deficiency severe malnutrition

Keywords: acute respiratory infection acute lower respiratory infection diarrhea
a study of thioctic acid and deprenyl in hiv-infected patients with dementia

Conditions: Cognitive Disorders; HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to hiv-infected patients who have mild to moderate dementia (a decline in their mental abilities).

patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active drug on an open-label basis. patients must have seven clinic visits.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * antiretrovirals provided dose has been stable for at least 6 weeks prior to study entry. patients must have: * hiv seropositivity. * mild to moderate cognitive impairment (problems with short term memory, concentration, and feeling slowed down). * no active opportunistic cns infection. * ability to give informed consent. prior medication: allowed: * prior antiretrovirals provided dose has been stable for at least the past 6 weeks. * prior thioctic acid or deprenyl. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * severe premorbid psychiatric illness including schizophrenia and major depression that would interfere with study compliance. * cns neoplasms. * any other clinically significant condition or laboratory abnormality that would preclude participation on study. * current participation in other drug studies. concurrent medication: excluded: * chemotherapy for malignancy. patients with the following prior conditions are excluded: * history of chronic neurological disorders such as serious head injury, documented stroke, multiple sclerosis, uncontrolled epilepsy, tourette's syndrome, and other neurodegenerative processes such as huntington's disease. * prior participation in this study. * history of adverse reaction/allergy to thioctic acid or deprenyl. prior medication: excluded: * other investigational drugs within 30 days prior to study entry.

Keywords: drug therapy, combination cognition disorders acquired immunodeficiency syndrome aids-related complex thioctic acid selegiline
impact of a free distribution of paracetamol to osteoarthritic patients on non-steroidal anti-inflammatory drugs (nsaid) and proton pump inhibitors (ppi) prescription

Conditions: Osteoarthritis

Summary: paracetamol is recommended as first line treatment for pain control in osteoarthritis, but it is not included in list of drugs than can be prescribed in charge of national health system by general practitioners. the hypothesis is that removing this economical barrier the investigators can decrease the prescription of nsaid and of the proton pump inhibitors (ppi), often given for gastric bleeding prophylaxis in nsaid chronic users. as secondary outcome, opioids use was also monitored to see. aim of the study is to test if allowing prescription of free paracetamol decreases the prescription of nsaid in osteoarthritic patients.

the trial was conducted in two primary care units of the province of reggio emilia. the units have about 34.000 inhabitants. in this units 16 general practitioners are active, the average beneficiaries per general practitioner are 1500, about one fourth over 65 years old.

Eligibility criteria:
inclusion criteria: * patients with osteoarthritis assisted by a general practitioners working in reggio emilia province who agreed to participate in the study exclusion critera: - none

Keywords: paracetamol ppi opioids nsaid drug prescription
asthma and osteopathic manipulative treatment

Conditions: Asthma

Summary: the effect of osteopathic manipulative treatment (omt) has been studied in adult patients with chronic obstructive pulmonary disease (copd) and children with asthma, however, to the authors' knowledge, no current studies have evaluated the non-immediate effects of omt on pulmonary function in adults with chronic asthma using spirometry. the objective of the current study was to quantify the immediate, intermediate, and long-term effects of omt on adult patients with a history of asthma. the quantitative effects were measured with a spirometry device and include the forced expiratory volume in one second (fev1), the forced vital capacity (fvc), the fev1/fvc ratio, and the peak expiratory flow (pef). these four values are used clinically in the diagnosis and management of asthma. the long-term, subjective effects were measured via the asthma quality of life questionnaire with standardized activities (aqlq(s)). the study was conducted over a period of eight weeks. during week 0, participants completed the initial aqlq and performed baseline spirometry testing. during weeks 1, 2, and 3 of the study, a standard omt protocol was performed on each participant, followed by spirometry testing to measure the immediate effect. spirometry testing was then performed again three days after each treatment to measure the intermediate effect of omt. during week 7, participants completed the post-omt aqlq(s) and performed spirometry testing once more to measure the long-term effects of omt. the omt protocol performed on each patient included treatments to address somatic dysfunctions of the head, cervical spine, thoracic spine, ribs, and respiratory diaphragm. the authors hypothesized that omt would improve pulmonary function, both subjectively and objectively. the authors predicted an increased overall mean aqlq(s) score as well as an increased mean score within each domain, including symptoms, activity limitations, emotional function, and environmental stimuli. the authors also predicted a significant increase in the mean fev1/fvc ratio, and pef three days after each omt session and a significant increase four weeks after the final omt session, but no increase immediately after omt.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * previously diagnosed with asthma exclusion criteria: * current smoker * diagnosed with any other respiratory disease besides asthma * receiving omm from a licensed physician, chiropractic treatment, or massage therapy for 30 days prior to and during the study

Keywords: osteopathic manipulative medicine spirometry respiratory omm omt osteopathic manual medicine osteopathic manipulative treatment osteopathic manual treatment
internet-based stress recovery program for adolescents

Conditions: Stress, Psychological

Summary: the study aims to evaluate the feasibility and efficacy of the internet-based stress recovery program for adolescents.

the forest-a is a third-wave cognitive behavioral therapy and mindfulness-based internet-delivered 4-week psychosocial intervention for recovery from stress, which was initially developed for healthcare workers and is now adapted for adolescents. the program comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, with psychologist engagement on-demand. each module includes psychoeducation and exercises. the program will be delivered in lithuanian. the intervention will be evaluated using the two-arm randomized controlled trial with intervention and care as usual condition at pre-test and post-test.

Eligibility criteria:
inclusion criteria: * recent exposure to life-stressor. * students of high schools in lithuania. * comprehending lithuanian. * parental and own consent for minor-aged participants (\< 18 years)/only own consent for adolescents aged 18 years or older to participate in the study provided. * have access to a device (such as a tablet, phone or computer) with an internet connection. exclusion criteria: * acute psychiatric condition/crisis. * no recent life-stressor exposure, or low levels of stress.
a real-world study of tuberculosis incidence in as, psa, or pso patients treated with secukinumab in brazil

Conditions: Tuberculosis

Summary: this was a retrospective observational study that relied on data extracted from patient's chart review at the participating centers. data was entered into an electronic case report form (ecrf) designed to capture all relevant information to achieve the study objectives. after the ethical approval for each participating site, the respective investigator and/or designated qualified study staff were responsible for including all eligible patients in a consecutive manner and entering their information into the ecrf. patients were primarily identified with ankylosing spondylitis (as), psoriatic arthritis (psa), and psoriasis (pso) diagnosis according to the international classification of diseases (icd)-10 code (m45, m07, and l40, respectively). alternatively, the written diagnosis from applicable departments, such as payment, computing, or data office were also used for patient screening. potentially eligible patients had their charts reviewed for all selection criteria. inclusion was performed up to the number of patients determined for each site prior to study initiation or up to completion of sample size. patient's identification (name, address, and other identifiable data) was not collected and remained confidential.


Eligibility criteria:
inclusion criteria: 1. documented diagnosis with as, psa, or pso, regardless of its severity, by a physician as per patient chart up to secukinumab introduction. 2. patient treated with secukinumab monotherapy for at least 24 months since 01 january 2016 in brazil, in accordance with local labelling approval. 3. biologic-naïve or secondary-naïve patient, who was not using biologic drug for at least 3 months prior to secukinumab introduction. 4. medical history available from the entire study period i.e., at least 6 months before and 24 months after secukinumab introduction. exclusion criteria: 1. no access or availability of patient medical chart. 2. patient who did not use approved dosing regimens for secukinumab therapy, as per local label. 3. patient with confirmed clinical history of active tuberculosis or mendelian susceptibility to mycobacterium diseases prior to secukinumab use. 4. patient treated with systemic corticosteroid doses with immunosuppressant features (prednisone dose higher than 10 milligrams \[mg\] or its equivalent) for at least 2 consecutive weeks or other concomitant immunosuppressant drug during the study period.

Keywords: ankylosing spondylitis psoriatic arthritis psoriasis